头孢曲松在儿童严重感染中的疗效与安全性。
Efficacy and safety of ceftriaxone in serious pediatric infections.
作者信息
Aronoff S C, Murdell D, O'Brien C A, Klinger J D, Reed M D, Blumer J L
出版信息
Antimicrob Agents Chemother. 1983 Nov;24(5):663-6. doi: 10.1128/AAC.24.5.663.
Abstract
Thirty-four patients aged 1 month to 19 years were treated with ceftriaxone for suspected bacterial infections. Bacterial pathogens were isolated from 25 children. The overall bacterial cure rate was 88%, with an overall clinical response rate of 96%. No side effects requiring cessation of therapy were observed. Ceftriaxone proved to be safe and effective in the treatment of serious infections in children.
摘要
34名年龄在1个月至19岁之间的患者因疑似细菌感染接受了头孢曲松治疗。从25名儿童中分离出了细菌病原体。总体细菌治愈率为88%，总体临床有效率为96%。未观察到需要停止治疗的副作用。头孢曲松被证明在治疗儿童严重感染方面安全有效。
相似文献
1
Efficacy and safety of ceftriaxone in serious pediatric infections.头孢曲松在儿童严重感染中的疗效与安全性。
Antimicrob Agents Chemother. 1983 Nov;24(5):663-6. doi: 10.1128/AAC.24.5.663.
2
Once-daily ceftriaxone therapy for serious bacterial infections in children.儿童严重细菌感染的每日一次头孢曲松治疗
Antimicrob Agents Chemother. 1985 Feb;27(2):181-3. doi: 10.1128/AAC.27.2.181.
3
Twice daily ceftriaxone therapy for serious bacterial infections in children.
J Antimicrob Chemother. 1984 May;13(5):511-6. doi: 10.1093/jac/13.5.511.
4
Ceftriaxone therapy of meningitis and serious infections.头孢曲松治疗脑膜炎和严重感染。
Am J Med. 1984 Oct 19;77(4C):50-3.
5
Efficacy of ceftriaxone in serious bacterial infections.头孢曲松在严重细菌感染中的疗效。
Antimicrob Agents Chemother. 1982 Mar;21(3):402-6. doi: 10.1128/AAC.21.3.402.
6
Efficacy of ceftriaxone in treatment of serious childhood infections.头孢曲松治疗儿童严重感染的疗效。
J Pediatr. 1983 Jul;103(1):141-5. doi: 10.1016/s0022-3476(83)80802-6.
7
Ceftriaxone therapy in pediatric patients.
Am J Dis Child. 1983 Nov;137(11):1048-51. doi: 10.1001/archpedi.1983.02140370010004.
8
Ceftriaxone for the treatment of serious infections.
Am J Dis Child. 1983 Nov;137(11):1044-7. doi: 10.1001/archpedi.1983.02140370006003.
9
[Clinical evaluation of ceftriaxone in the pediatric field].
Jpn J Antibiot. 1984 Nov;37(11):2027-33.
10
Ceftriaxone therapy of serious bacterial infections.严重细菌感染的头孢曲松治疗。
J Antimicrob Chemother. 1983 Jul;12(1):65-78. doi: 10.1093/jac/12.1.65.
引用本文的文献
1
Adverse Drug Reactions Resulting From the Use of Chiral Medicines Amoxicillin, Amoxicillin-Clavulanic Acid, and Ceftriaxone: A Mixed Prospective-Retrospective Cohort Study.使用手性药物阿莫西林、阿莫西林-克拉维酸和头孢曲松导致的药物不良反应：一项前瞻性与回顾性混合队列研究。
Inquiry. 2024 Jan-Dec;61:469580241273323. doi: 10.1177/00469580241273323.
2
Reversing the myths obstructing the determination of optimal age- and disease-based drug dosing in pediatrics.破除阻碍确定儿科基于年龄和疾病的最佳药物剂量的错误观念。
J Pediatr Pharmacol Ther. 2011 Jan;16(1):4-13.
3
Ceftazidime as initial therapy for suspected bacterial infections in hospitalized pediatric patients.头孢他啶作为住院儿科患者疑似细菌感染的初始治疗药物。
Antimicrob Agents Chemother. 1984 Sep;26(3):318-21. doi: 10.1128/AAC.26.3.318.
4
Once-daily ceftriaxone therapy for serious bacterial infections in children.儿童严重细菌感染的每日一次头孢曲松治疗
Antimicrob Agents Chemother. 1985 Feb;27(2):181-3. doi: 10.1128/AAC.27.2.181.
本文引用的文献
1
Multiple intravenous dose pharmacokinetics of ceftriaxone in man.头孢曲松在人体中的多次静脉给药药代动力学
Chemotherapy. 1981;27 Suppl 1:47-56. doi: 10.1159/000238029.
2
Comparative activities of 13 beta-lactam antibiotics.13种β-内酰胺类抗生素的比较活性
Antimicrob Agents Chemother. 1982 Jun;21(6):925-34. doi: 10.1128/AAC.21.6.925.
3
Reports on cephtriaxone (Rocephin). Introduction and review.关于头孢曲松（罗氏芬）的报告。引言与综述。
Chemotherapy. 1981;27 Suppl 1:1-8. doi: 10.1159/000238020.
4
Pharmacokinetics and tolerance of ceftriaxone in humans after single-dose intramuscular administration in water and lidocaine diluents.头孢曲松在水中和利多卡因稀释剂中单剂量肌内注射后在人体中的药代动力学和耐受性。
Antimicrob Agents Chemother. 1982 Jun;21(6):957-62. doi: 10.1128/AAC.21.6.957.
5
Efficacy of ceftriaxone in serious bacterial infections.头孢曲松在严重细菌感染中的疗效。
Antimicrob Agents Chemother. 1982 Mar;21(3):402-6. doi: 10.1128/AAC.21.3.402.
6
Single-dose pharmacokinetics of ceftriaxone in infants and young children.头孢曲松在婴幼儿中的单剂量药代动力学。
Antimicrob Agents Chemother. 1982 Feb;21(2):248-53. doi: 10.1128/AAC.21.2.248.
7
Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative.新型头孢菌素衍生物Ro 13-9904的体外比较研究
Antimicrob Agents Chemother. 1981 Mar;19(3):435-42. doi: 10.1128/AAC.19.3.435.
8
In vitro susceptibility of cephalothin-resistant Enterobacteriaceae and Pseudomonas aeruginosa to Amikacin and selected new beta-lactam agents.耐头孢噻吩肠杆菌科细菌和铜绿假单胞菌对阿米卡星及某些新型β-内酰胺类药物的体外敏感性
Antimicrob Agents Chemother. 1982 May;21(5):753-7. doi: 10.1128/AAC.21.5.753.
Zotero 插件